hotspot -WSS

hotspot

author：fashion 2025-09-07 17:26:52 - browse：56489

Two boxes of Ozempic stack on each other, while one lean on the stack tilted — health coverage from STAT — SEBASTIEN BOZON/AFP via Getty Images

Novo Nordisk’s Ozempic cut the risk of death in a trial of patients with type 2 diabetes and chronic kidney disease, suggesting it may offer some added benefits over other classes of drugs approved to treat this population.

Specifically, the diabetes drug cut the risk of cardiovascular-related deaths by 29% and all-cause deaths by 20%. Given the study parameters, this implies that over three years, 39 people would need to be treated to prevent one death from any cause, according to new results presented Friday at a meeting of the European Renal Association and published in the New England Journal of Medicine.

Ozempic also lowered the risk of major heart complications — including cardiovascular-related death, heart attack, or stroke — by 18%, driven primarily by the reduced rate of heart-linked death.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Florida health officials providing scant details on measles cases

leisure time

entertainment

WSS

Ancient Greek ideas underpin modern concepts of pregnancy

Boston competes with Raleigh

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

White House pharmacy plagued with problems, investigation finds

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

explore

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

The cancer drug shortage isn’t new — and neither are the solutions

Medicare Advantage insurers face 0.2% cut to 2025 payments

Drug repurposing or repositioning? The language matters

White House pharmacy plagued with problems, investigation finds

BioMarin wins approval for gene therapy to treat hemophilia A

$1 billion proposal to grow Boston, Massachusetts biotech

Alkermes shareholders re

Philips to halt sales of sleep apnea machines in U.S.

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Boston competes with Raleigh

entertainment

For AI in health care standards, federal regulators join with industry group

Merck, Johnson & Johnson CEOs will testify on high drug prices

Ancient Greek ideas underpin modern concepts of pregnancy

Investment in vaccine development is lagging, report finds

Biden's 'march

The untold story of TV’s first prescription drug ad

knowledge

leisure time

entertainment

Wikipedia